Global Cancer Incidence and Mortality Forecasts for 2018
Global cancer cases were projected to reach approximately 18.1 million new diagnoses in 2018, with mortality figures around 9.6 million deaths, according to the International Agency for Research on Cancer. These estimates highlighted the rising burden of the disease in both developed and developing nations, driven by aging populations and lifestyle factors.
Lung, breast, and colorectal cancers remained the most commonly diagnosed types, accounting for a significant share of incident cases worldwide. The data underscored the urgent need for early detection programs and scalable treatment infrastructure in emerging markets.
Oncology Market Growth and Investment Trends
The global oncology market was forecast to surpass $150 billion by 2018, with immunotherapies and targeted therapies driving the majority of revenue growth. Companies such as Roche, Merck, and Bristol-Myers Squibb led market capitalization rankings, supported by strong pipeline data and regulatory approvals.
Venture capital and public market investments in cancer biotechnology remained robust, with firms like Juno Therapeutics and Kite Pharma attracting significant funding for cell therapy platforms. The sector's valuation was further bolstered by the FDA's accelerated approval pathways for breakthrough therapies as reported by Forbes.
Key Regulatory and Technology Developments
The U.S. Food and Drug Administration approved multiple oncology drugs in 2018, including novel checkpoint inhibitors and CAR-T cell therapies, expanding the treatment landscape for hematologic and solid tumor cancers. Regulatory guidance on companion diagnostics also evolved to support precision medicine approaches.
Advances in genomic sequencing and liquid biopsy technologies enabled more personalized treatment strategies, with companies like Illumina and Guardant Health releasing commercial tests. The integration of real-world evidence into clinical trial designs accelerated drug development timelines per SEC filings.